Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Profit After Tax (2019 - 2025)

Cyclerion Therapeutics has reported Profit After Tax over the past 7 years, most recently at -$976000.0 for Q3 2025.

  • Quarterly results put Profit After Tax at -$976000.0 for Q3 2025, down 34.99% from a year ago — trailing twelve months through Sep 2025 was -$2.2 million (up 59.14% YoY), and the annual figure for FY2024 was -$3.1 million, up 75.72%.
  • Profit After Tax for Q3 2025 was -$976000.0 at Cyclerion Therapeutics, down from -$324000.0 in the prior quarter.
  • Over the last five years, Profit After Tax for CYCN hit a ceiling of $44.1 million in Q4 2022 and a floor of -$16.2 million in Q2 2021.
  • Median Profit After Tax over the past 5 years was -$4.2 million (2023), compared with a mean of -$3.3 million.
  • Biggest five-year swings in Profit After Tax: skyrocketed 509.28% in 2022 and later tumbled 104.07% in 2023.
  • Cyclerion Therapeutics' Profit After Tax stood at -$10.8 million in 2021, then skyrocketed by 509.28% to $44.1 million in 2022, then tumbled by 104.07% to -$1.8 million in 2023, then skyrocketed by 129.53% to $530000.0 in 2024, then tumbled by 284.15% to -$976000.0 in 2025.
  • The last three reported values for Profit After Tax were -$976000.0 (Q3 2025), -$324000.0 (Q2 2025), and -$1.4 million (Q1 2025) per Business Quant data.